Firms Tout Data On Next-Gen Stents, But FDA Hurdles May Be Steep

At major cardio meetings this month, stent makers – both start-ups and traditional market leaders – showcased promising data on several next-gen drug-eluting stent systems intended to improve safety, but cardiologists worry that FDA requirements may be too steep.